HighTower Advisors LLC Sells 591,434 Shares of Johnson & Johnson $JNJ

HighTower Advisors LLC cut its position in shares of Johnson & Johnson (NYSE:JNJ) by 5.6% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 9,892,767 shares of the company’s stock after selling 591,434 shares during the quarter. Johnson & Johnson makes up 2.4% of HighTower Advisors LLC’s investment portfolio, making the stock its 5th largest position. HighTower Advisors LLC owned about 0.41% of Johnson & Johnson worth $2,512,466,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of JNJ. NorthStar Asset Management LLC NJ boosted its position in Johnson & Johnson by 3.1% during the second quarter. NorthStar Asset Management LLC NJ now owns 5,922 shares of the company’s stock worth $1,504,000 after acquiring an additional 180 shares during the last quarter. Convergence Financial LLC raised its holdings in Johnson & Johnson by 85.8% in the 2nd quarter. Convergence Financial LLC now owns 9,428 shares of the company’s stock valued at $2,394,000 after acquiring an additional 4,354 shares during the last quarter. TBH Global Asset Management LLC lifted its stake in shares of Johnson & Johnson by 1.0% during the 2nd quarter. TBH Global Asset Management LLC now owns 15,852 shares of the company’s stock worth $4,026,000 after purchasing an additional 150 shares during the period. Bridgewater Advisors Inc. boosted its holdings in shares of Johnson & Johnson by 6.1% during the second quarter. Bridgewater Advisors Inc. now owns 22,989 shares of the company’s stock worth $5,849,000 after purchasing an additional 1,330 shares during the last quarter. Finally, Affinity Investment Advisors LLC boosted its holdings in shares of Johnson & Johnson by 11.0% during the second quarter. Affinity Investment Advisors LLC now owns 8,462 shares of the company’s stock worth $2,149,000 after purchasing an additional 839 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson News Summary

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: The FDA approved Imaavy (nipocalimab) as the first specifically indicated treatment for warm autoimmune hemolytic anemia (wAIHA) in adults and patients aged 12 and older who currently or previously received corticosteroids. The approval expands J&J’s immunology franchise, addresses an unmet need in a rare, life-threatening disease and provides another potential growth driver for the company’s FcRn antibody platform. FDA approves Imaavy for wAIHA
• Positive Sentiment: Analysts and industry coverage view Imaavy’s approval as progress toward J&J’s goal of achieving approximately $5 billion in peak sales for the drug, although the initial wAIHA patient population is relatively small. The company also received European approval to expand the use of its cancer medicine Tecvayli, broadening its oncology reach. Imaavy and Tecvayli approvals
• Positive Sentiment: J&J’s recent operating momentum remains supportive: its latest quarterly results exceeded revenue and earnings expectations, revenue rose year over year, and management set fiscal 2026 EPS guidance of $11.60-$11.75. J&J pipeline momentum
• Neutral Sentiment: Healthcare stocks have benefited from investors seeking stability amid weakness or elevated valuations in technology shares. J&J’s defensive profile and dividend consistency may support demand, though higher Treasury yields make dividend stocks less relatively attractive. Investors seek stability in J&J
• Neutral Sentiment: J&J shares have risen more than 50% over the past year and are near their 12-month high. Commentary describes the stock as a hold, suggesting that much of the pipeline and earnings optimism may already be reflected in the valuation.
• Negative Sentiment: A Louisiana jury awarded $10 million in a talc-related mesothelioma case, renewing concerns about the company’s asbestos litigation liabilities despite J&J’s proposed multibillion-dollar settlement. FDA approval and talc litigation coverage
• Negative Sentiment: Investors continue to monitor the rapid erosion of Stelara following patent and exclusivity losses, making successful launches such as Imaavy important for replacing declining revenue from older products. J&J patent-cliff comparison

Analysts Set New Price Targets

Several research firms recently commented on JNJ. HSBC set a $290.00 target price on Johnson & Johnson and gave the company a “buy” rating in a research note on Monday, July 6th. Argus set a $300.00 price target on Johnson & Johnson in a report on Wednesday, July 29th. Raymond James Financial set a $280.00 price objective on shares of Johnson & Johnson in a report on Monday, August 3rd. Scotiabank reissued an “outperform” rating and issued a $305.00 target price on shares of Johnson & Johnson in a research report on Thursday, July 16th. Finally, Bank of America boosted their target price on shares of Johnson & Johnson from $254.00 to $263.00 and gave the company a “neutral” rating in a report on Friday, July 10th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $268.22.

Johnson & Johnson Stock Performance

Johnson & Johnson stock opened at $273.28 on Wednesday. The company has a market cap of $658.58 billion, a price-to-earnings ratio of 31.67, a price-to-earnings-growth ratio of 2.61 and a beta of 0.24. Johnson & Johnson has a 12 month low of $173.33 and a 12 month high of $276.47. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.09 and a quick ratio of 0.81. The stock’s 50-day moving average is $256.59 and its 200-day moving average is $243.36.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.84 by $0.06. The business had revenue of $25.31 billion during the quarter, compared to analysts’ expectations of $25.06 billion. Johnson & Johnson had a return on equity of 32.42% and a net margin of 21.48%.The company’s revenue for the quarter was up 6.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.77 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. Equities analysts anticipate that Johnson & Johnson will post 11.61 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th will be paid a dividend of $1.34 per share. This represents a $5.36 annualized dividend and a yield of 2.0%. The ex-dividend date is Tuesday, August 25th. Johnson & Johnson’s payout ratio is currently 62.11%.

Insider Buying and Selling at Johnson & Johnson

In related news, EVP Vanessa Broadhurst sold 23,054 shares of the stock in a transaction on Monday, July 20th. The stock was sold at an average price of $251.27, for a total value of $5,792,778.58. Following the completion of the sale, the executive vice president directly owned 23,003 shares in the company, valued at approximately $5,779,963.81. This represents a 50.06% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Jennifer L. Taubert sold 15,000 shares of the firm’s stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $263.36, for a total value of $3,950,400.00. Following the completion of the transaction, the executive vice president directly owned 194,451 shares in the company, valued at $51,210,615.36. This trade represents a 7.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 63,972 shares of company stock worth $16,245,605. 0.16% of the stock is currently owned by insiders.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.